AbCellera Biologics Inc. (ABCL)

Market Cap	788.63M
Revenue (ttm)	32.96M
Net Income (ttm)	-175.80M
Shares Out	295.37M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,714,955
Open	2.690
Previous Close	2.710
Day's Range	2.620 - 2.720
52-Week Range	2.335 - 6.060
Beta	0.35
Analysts	Buy
Price Target	8.50 (+218.35%)
Earnings Date	Nov 4, 2024

About ABCL

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 586
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL
• Website: https://www.abcellera.com

Analyst Forecast

According to 3 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 218.35% from the latest price.

Price Target

$8.5

(218.35% upside)

Analyst Consensus: Buy